HER2+ (HR−/HER2+ and HR+/HER2+) patients with BCLM were more frequently diagnosed with de novo stage IV breast cancer than HER2- (HR+/HER2- and triple-negative) patients (p = 0.002). This evidence concerns the gene ERBB2 and breast cancer.